Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011;6(9):e24604.
doi: 10.1371/journal.pone.0024604. Epub 2011 Sep 16.

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis

Anne Waschbisch  1 , Monika Atiya, Ralf A Linker, Sergej Potapov, Stefan Schwab, Tobias Derfuss
Affiliations
Clinical Trial

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis

Anne Waschbisch et al. PLoS One. 2011.

Abstract

The expression of selected microRNAs (miRNAs) known to be involved in the regulation of immune responses was analyzed in 74 patients with relapsing remitting multiple sclerosis (RRMS) and 32 healthy controls. Four miRNAs (miR-326, miR-155, miR-146a, miR-142-3p) were aberrantly expressed in peripheral blood mononuclear cells from RRMS patients compared to controls. Although expression of these selected miRNAs did not differ between treatment-naïve (n = 36) and interferon-beta treated RRMS patients (n = 18), expression of miR-146a and miR-142-3p was significantly lower in glatiramer acetate (GA) treated RRMS patients (n = 20) suggesting that GA, at least in part, restores the expression of deregulated miRNAs in MS.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: AW has received funding for travel or speaker honoraria from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Merck Serono, and Teva Pharmaceuticals. RL has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Merck Serono, Novartis, Sanofi-Aventis, and Teva Pharmaceuticals as well as research support from Biogen Idec, Merck Serono, Novartis, and Teva Pharmaceuticals. TD has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec/Elan Corporation, Novartis, Merck Serono, and Teva Pharmaceuticals as well as research support from Merck Serono and Novartis. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. The commercial companies mentioned above did not fund this particular study.

Figures

Figure 1
Figure 1. miRNA dysregulation in MS and the impact of immunomodulatory treatment.
The relative expression of the mature miRNAs miR-326, miR-155, miR-146a and miR-142-3p in PBMC derived from healthy donors (HD, n = 32), treatment-naïve patients with RRMS (n = 36) and glatiramer acetate (GA, n = 20) or Interferon-beta (IFN, n = 18) was analyzed by real-time PCR. Bars represent the mean + S.E.M. * p<0,05; **p<0,005.
Figure 2
Figure 2. ROC analysis.
To assess the sensitivity and specificity of miRNAs to predict disease, receiver operator characteristic curves were computed based on the relative miRNA expression in treatment-naïve patients and healthy controls. The ROC curves for miR-326 and miR-142-3p are exemplary depicted.
See this image and copyright information in PMC

References

    1. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, et al. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008;10:R101. - PMC - PubMed
    1. Tang Y, Luo X, Cui H, Ni X, Yuan M, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009;60:1065–1075. - PubMed
    1. Alevizos I, Alexander S, Turner RJ, Illei GG. MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjogren's syndrome. Arthritis Rheum. 2011;63:535–544. - PMC - PubMed
    1. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20. - PubMed
    1. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010;10:111–122. - PubMed

Publication types

MeSH terms